Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W24 AI support agent builder at 80% resolution time reduction and 71% ticket deflection; $500K from a16z/Greylock/YC/Netflix competing with Intercom Fin for customer support AI workflow automation.
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 additional investors — providing customer support teams with an AI agent builder that translates existing support processes and workflows into predictable, reliable AI automation, achieving 80% reduction in resolution time and 71% ticket deflection for deployed teams. Founded in 2023 and targeting customer support leaders at growth-stage software companies, Duckie enables support teams to deploy AI agents in minutes without engineering dependency.
Vancouver-based antibody discovery platform with 104+ partner programs; $75M FY2025 revenue. Expanding into wholly owned assets with ABCL635 in Phase 1 for vasomotor symptoms.
AbCellera Biologics was founded in 2012 in Vancouver, Canada by Carl Hansen, growing out of research at the University of British Columbia. The company built a high-throughput antibody discovery platform integrating microfluidics, genomics, single-cell sequencing, and AI/ML to rapidly identify therapeutic antibody candidates from natural immune responses. AbCellera played a prominent role in the COVID-19 pandemic by discovering bamlanivimab for Eli Lilly in under 90 days.\n\nAbCellera's partnership model operates on a discovery fee plus downstream milestone and royalty structure, having started over 104 partner-initiated programs with downstream participation as of December 2025. Partners include major pharmaceutical companies and biotechs; the company expanded its collaboration with AbbVie in 2025 to develop T-cell engagers for oncology. Total FY2025 revenue was $75 million ($47M from royalties/licensing, $27M from partnered program work), compared to $29 million in 2024—a dramatic increase driven by royalty flows from approved medicines.\n\nIn 2025 AbCellera began transitioning from pure partnership model toward wholly owned therapeutic assets, with ABCL635 (a GnRH receptor antibody for vasomotor symptoms) entering Phase 1. The company maintains approximately $700 million in liquidity, providing a long runway. AbCellera is considered a foundational infrastructure provider for the antibody-based drug discovery ecosystem.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.